Current and future impact of green chemistry on the pharmaceutical industry

Future Medicinal Chemistry

Volumn 1, Issue 4, 2009, Pages 571-575

  Fortunak, Joseph M ^a  

^a HOWARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PELITREXOL; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; PREGABALIN; SERTRALINE; UNCLASSIFIED DRUG;

COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; EDITORIAL; HEALTH CARE ORGANIZATION; HYDROGENATION; MEDICAL EDUCATION; MEDICAL SOCIETY; PRIORITY JOURNAL;

BIOENGINEERING; DRUG INDUSTRY; GREEN CHEMISTRY TECHNOLOGY; PHARMACEUTICAL PREPARATIONS;

EID: 77953433923     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.60     Document Type: Editorial

References (18)

1. Malthus TR. An Essay on the Principle of Population. Cambridge University Press, Cambridge, UK (1992).
2. Organization for Economic Cooperation and Development. Governance for Sustainable Development: Five OECD Case Studies. 4, 1-345 (2002).
3. Poliakoff M, Fitzpatrick MJ, Farren TR, Anastas PT. Green chemistry, science and the politics of change. Science 298, 807-810 (2002).
4. Anastas PT, Warner JC. Green Chemistry, Theory and Practice. Oxford University Press, NY, USA, 1-19 (1998).
5. Carson RL, Burstyn E, Wilson EO. Silent Spring. 40th Anniversary Edition. Houghton Mifflin Harcourt, Boston, MA, USA (2002).
6. Anderson NG. The impact of process chemists and engineers on green chemistry. Org. Process Res. Dev. 12(6), 1019-1020 (2008).
7. Yadav GD, Leo J. Ceasar kinetics of selective formation of ibuprofenamide by phase transfer catalyzed oxidation of 2-(4-isobutylphenyl)propionitrile with basic hydrogen peroxide. Org. Process Res. Dev. 12(4), 740-747 (2008).
8. Farina V, Shua C, Zheng X et al. Secondgeneration process for the HCV protease inhibitor BILN 2061: a greener approach to ru-catalyzed ring-closing metathesis. Org. Process Res. Dev. 13(2), 250-254 (2009).
9. Slater CS, Savelski M. A method to characterize the greenness of solvents used in pharmaceutical manufacturing. Environ. Sci. Health A Environ. Sci. Eng. Toxic Hazard Subst. Control. 42, 1595-1605 (2007).
10. Constable DJ, Jiminez-Gonzalez C, Henderson RK. Perspective on solvent use in the pharmaceutical industry. Org. Process Res. Dev. 11(1), 133-137 (2007).
11. Ro DK, Paradise EM, Ouellet M et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440, 940-943 (2006).
12. Harrington PJ, Brown JD, Foderaro T, Hughes RC. Research and development of a second-generation process for oseltamivir phosphate, prodrug for a neuraminidase inhibitor. Org. Process Res. Dev. 8(1), 86-91 (2004).
13. Hu S, Kelly S, Lee S, Tao J, Flahive E. Efficient chemoenzymatic synthesis of pelitrexol via enzymic differentiation of a remote stereocenter. Org. Lett. 8(8), 1653-1655 (2006).
14. Taber GP, Pfisterer DM, Colbert JC. A new and simplified process for preparing n-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2h)- naphthalenylidene] methanamine and a telescoped process for the synthesis of (1s-cis)-4-(3,4- dichlorophenol)-1,2,3,4- tetrahydro-n-methyl-1-naphthalenamine mandelate: key intermediates in the synthesis of sertraline hydrochloride. Org. Process Res. Dev. 8(3), 385-388 (2004).
15. Noh H-K, Lee JS, Kim U et al. Synthesis of the intermediate of gemifloxacin by the chemoselective hydrogenation of 4-cyano-3- methoxyimino-1-(n-tert-butoxycarbonyl) pyrrolidine. Part 2: the palladium catalysts in acidic media. Org. Process Res. Dev. 8(5), 788-795 (2006).
16. Wallace DJ, Campos KR, Schultz CS et al. New efficient asymmetric synthesis of taranabant, a cb1r inverse agonist for the treatment of obesity. Org. Process Res. Dev. 13(1), 84-90 (2009).
17. Martinez CA, Hu S, Dumond Y, Tao J, Kelleher P, Tully Y. Development of a chemoenzymatic manufacturing process for pregabalin. Org. Process Res. Dev. 12(3), 392-398 (2008).
18. Scherzer R, Pharma API. The business case for PATs. Presented at: Influencing Change in the Regulatory Environment. API Technical Group 2003 PhRMA API Workshop, Dorado, Puerto Rico, April 28-May 1, 2003.